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Supplementary Figure 1: Analysis of monocyte subsets and lineage relationships. (a) Gating 
strategy for definition of MDP and cMoP populations in BM of Cx3cr1GFP/+ mice related to Fig. 1a. MDP 
was defined as CD11c-MHC-II- cells from live CD45+Lin-CD11b-CD117+CD115+GFP+ population. For 
cMoP Ly6C+CD11c-MHC-II- subset was gated from live CD45+Lin-CD11b-CD117+CD115+GFP+ 
population. (Lin: CD3, CD45R/B220, CD19, NK1.1, Ly6G, CD49b). (b) Gating strategy for identification 
of monocyte and GC (top) or MDP and cMoP (bottom) subpopulations in wild-type (Cx3cr1+/+) mice. 
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Supplementary Figure 2: Validation of gating strategy in Nr4a1-GFP mice and adoptive transfer 
experiments. (a) Flow cytometry plot depicting validation of CX3CR1 based gating strategy 
(corresponding to gating in Cx3cr1GFP/+ mice, in Fig. 1a) precisely identifies Nr4a1-GFP+CD43+Ly6Clo/- 
monocytes in bone marrow. (b) Flow cytometry plot depicting validation of CX3CR1 independent gating 
strategy (corresponding to gating in wild type mice, in Supplementary Fig 1b) precisely defines Nr4a1-
GFP+CD43+Ly6Clo/- monocytes. 
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Supplementary Figure 3: Ly6Chi monocyte adoptive transfer experiments. (a) Sorting strategy for 
adoptive transfer of CD11b+GFP+Ly6Chi monocytes. (b) Schematic illustration of adoptive transfer and 
multicolor flow cytometry analysis of Ly6Chi monocytes from GFP+CD45.2+ mice into CD45.1+ recipients. 
(c) 4th and 5th rows of flow cytometry plots from Fig. 1d are shown. Donor CD45.2+CD11b+GFP+ cells are 
black. For comparison CD45.1+CD11b+Ly6Clo/-F4/80lo recipient monocytes are depicted in blue 
(representative of two experiments). 
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Supplementary Figure 4: Specificity and efficiency of Cre expression and Notch2 targeting. (a) 
Flow cytometry plot showing gradual expression of LysM-eGFP in myeloid cell subpopulations from 
cMoP to Ly6Clo monocytes. (b) Flow cytometry plot showing YFP expression in bone marrow of 
LysMCreRosaYFP or control RosaYFP mice. LysMCre is strongly active in monocytes (Ly6Chi and Ly6Clo) and 
granulocytes but not in other cell populations. (c) Quantitative RT-PCR in sorted bone marrow cells from 
GFP+Notch2ΔMy mice showing highest expression of Cre in N2-Ly6Chi and subsequent reduction in Ly6Clo 
monocytes (n=6). * P<0.05, ** P<0.01, *** P<0.001; 1way ANOVA with Bonferroni’s multiple comparison 
test. Error bars represent s.e.m. (d) Notch2 expression in Ly6Chi and Ly6Clo monocyte subpopulations 
isolated from BM of Notch2ΔCD11c mice (representative of two experiments). Littermate controls are shown 
for comparison. 
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Supplementary Figure 5: Myeloid cell populations in Notch2 deficient mice. (a) Monocyte 
subpopulation analysis based on CD115+ gating strategy reveals reduction of Ly6Clo but not Ly6Chi 
monocytes in GFP+Notch2ΔMy mice. Data are pooled from three experiments (n=8/11). (b) Absolute or 
relative numbers of granulocytes in GFP+Notch2ΔMy mice. Data are pooled from three experiments 
(n=8/10). (c) Relative frequency of monocytes by flow cytometry in Notch2ΔMy with wild-type Cx3cr1 
locus. Data are pooled from three experiments (n=9/11). (d) Myeloid cell populations in 
LysMCreNotch2+/+ and LysM+/+Notch2+/+ littermate control mice. Data are from three experiments 
(n=7/8). (e) Myeloid cell population analysis in N1ΔMy mice (n=8/9). Data are pooled from three 
experiments. (f) Myeloid cell population analysis in N1N2ΔMy mice. Data are pooled from two 
experiments (n=5/6). (a-f) * P<0.05, ** P<0.01, *** P<0.001; Student’s t test. Error bars represent s.e.m. 
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Supplementary Figure 6: Notch2 deficient BM Ly6Chi monocytes show impaired conversion 
potential in vivo. (a, b) Flow cytometry (a) and corresponding fluorescence minus one controls (FMO 
ctrls) (b) 4 days after adoptive transfer of Ly6Chi monocytes (corresponding to Fig. 4c) from control or 
Notch2 deficient CD45.2+GFP+ donors into CD45.1+ congenic recipients. (a) Transferred cells are shown 
in black and for comparison, recipient CD45.1+ (1st row), CD45.1+CD11b+ (2nd row), 
CD45.1+CD11b+Ly6Chi (3rd row) cells or CD45.1+CD11b+Ly6ChiF4/80lo monocytes (4th and 5th rows) are 
depicted in blue. 
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Supplementary Figure 7: Notch2 deficient peripheral Ly6Chi monocytes show impaired 
conversion potential in vivo. (a) Flow cytometry plots 4 days after adoptive transfer of pooled splenic 
and peripheral blood Ly6Chi monocytes from control or Notch2 deficient CD45.2+GFP+ donors into 
CD45.1+ congenic recipients. Transferred cells are shown in black and for comparison, recipient CD45.1+ 
(1st row), CD45.1+CD11b+ (2nd row), CD45.1+CD11b+Ly6Chi (3rd row) cells or 
CD45.1+CD11b+Ly6ChiF4/80lo monocytes (4th to 5th rows) are depicted in blue (representative of two 
experiments). 
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Supplementary Figure 8: Notch ligand DLL1 mediates monocyte conversion in vitro. (a) Gating 
strategy for definition and quantification of Ly6Clo monocyte-like cells in vitro. Ly6Clo monocyte-like cells 
(CD11b+GFP+Ly6Clo/-CD11cloCD43+MHC-IIlo/-) are calculated as a percentage of live CD11b+GFP+ cells. 
(b) Flow cytometry plot showing expression of CD115 and upregulation of GFP on in vitro converted 
Ly6Clo monocyte-like cells. Ex vivo isolated GFP+Ly6Chi BM monocytes served as a staining control. 
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Supplementary Figure 9: In vivo targeting of endothelial cells in mice. b(c) Specific β-galactosidase 
activity in capillaries and large vessels of peripheral muscle (top) and in aortic EC (en face preparations 
(bottom)) after treatment of lacZiEC or control mice with tamoxifen; scale bar 100µm. Image is a 
representative of two (muscle) or three (aorta) experiments. (d) PCR for floxed or recombined locus of 
Dll1 from heart (left), lung (middle) and peripheral muscle (right). Results are from one experiment 
representative of 4 experiments. (e) Quantitative RT-PCR analysis of Dll1 expression in sorted ECs from 
control or Dll1iΔEC mice. Pooled from three experiments (n=3). (f) Myeloid cell population analysis in 
Dll1+/+ or CreERT2 Dll1+/+ mice after tamoxifen treatment showing no influence of tamoxifen on Ly6Clo 
monocyte development. Data are pooled from two experiments (n=6/7). (g) Cell population analysis in 
Cdh5(PAC)-CreERT2 Dll1f/f mice showing no influence of Cdh5(PAC)-CreERT2 expression on Ly6Clo 
monocyte development. Data are pooled from three experiments (n=6/8). (e-g) * P<0.05, ** P<0.01, *** 
P<0.001; Student’s t test. Error bars represent s.e.m. 
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Supplementary Figure 10: In vivo targeting of arterial endothelial cells in mice. (a) β-galactosidase 
staining demonstrates specific staining in central arteries of splenic follicles, arteries of peripheral muscle 
and aorta in lacZiaEC mice. Scale bars 100µm. Results are from one experiment representative of two 
independent experiments. (b) PCR for floxed or recombined Dll1 locus (ΔDll1) from aortas (n=2). 
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Supplementary Table 1: Surface phenotype signatures for identification of 
distinct myeloid populations in vivo 
 
Population Phenotype 
MDP Lin-CD117+CD11b-CD115+CX3CR1+Ly6C-F4/80-CD11c-MHC-II- 
or 
Lin-CD117+CD11b-CD115+Ly6C-F4/80-CD11c-MHC-II- 
cMoP Lin-CD117+CD11b-CD115+CX3CR1+Ly6ChiF4/80-CD11c-MHC-II- 
or 
Lin-CD117+CD11b-CD115+Ly6ChiF4/80-CD11c-MHC-II- 
Ly6Chi Lin-CD117-CD11b+CX3CR1loLy6ChiF4/80lo/-CD11c-MHC-IIlo/-CD43- 
or 
Lin-CD117-CD11b+Ly6ChiF4/80lo/-CD11c-MHC-IIlo/-CD43- 
Ly6Clo Lin-CD117-CD11b+CX3CR1hiLy6Clo/-F4/80loCD11cloMHC-IIlo/-CD43+ 
or 
Lin-CD117-CD11b+Ly6Clo/-F4/80loCD11cloMHC-IIlo/-CD43+ 
GC Lin+CD11b+CX3CR1-Ly6Clo 
or 
Lin+CD11b+Ly6Clo 
Atypical cells 
(Ly6Clo) 
Lin-CD117-CD11b+CX3CR1hiLy6Clo/-F4/80loCD11c-MHC-IIhiCD43- 
or 
Lin-CD117-CD11b+Ly6Clo/-F4/80loCD11c-MHC-IIhiCD43- 
 
 
Lin: CD3, CD45R/B220, CD19, NK1.1, Ly6G, CD49b 
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Supplementary Table 2: Mouse models used in the study 
 
Abbreviations Mouse description Mouse background 
CD45.1+ B6.SJL-PtprcaPepcb/BoyJ B6 
GFP+ ctrl LysM+/+ Notch2lox/lox Cx3cr1GFP/+ B6 
GFP+ N2∆My LysMCre Notch2lox/lox Cx3cr1GFP/+ B6 
Ctrl LysM+/+ Notch2lox/lox B6 
N2∆My LysMCre Notch2lox/lox B6 
Ctrl LysM+/+ Notch1lox/lox B6 
N1∆My LysMCre Notch1lox/lox B6 
Ctrl LysM+/+ Notch1lox/lox Notch2lox/lox B6 
N1N2∆My LysMCre Notch1lox/lox Notch2lox/lox B6 
wt Dll1+/+ 129 
Dll1+/lacZ Dll1+/lacZ 129 
Ctrl Gt(ROSA)26Sor B6 
lacZiEC Cdh5(PAC)-CreERT2 
Gt(ROSA)26Sor 
B6 
lacZiaEC Bmx(PAC)-CreERT2 
Gt(ROSA)26Sor 
B6 
Ctrl  Dll1lox/lox Mixed, B6;129 
Dll1i∆EC Cdh5(PAC)-CreERT2 Dll1lox/lox Mixed, B6;129 
Dll1i∆aEC Bmx(PAC)-CreERT2 Dll1lox/lox Mixed, B6;129 
Ctrl Dll4lox/lox Mixed, B6;CD1 
Dll4i∆EC  Cdh5(PAC)-CreERT2 Dll4lox/lox Mixed, B6;CD1 
Dll1+/+ Dll1+/+ Mixed, B6;129 
CreERT2 Dll1+/+ Cdh5(PAC)-CreERT2 Dll1+/+ Mixed, B6;129 
Ctrl LysM+/+ Notch2+/+ B6 
LysMCre LysMCre Notch2+/+ B6 
Nr4a1-GFP Nr4a1-EGFP/Cre B6 
LysM-eGFP LysM-EGFP B6 
RosaYFP LysM+/+ Gt(ROSA)YFP26Sor B6 
LysMCre;RosaYFP LysMCre Gt(ROSA)YFP26Sor B6 
GFP+ ctrl CD11cCre Notch1lox/+ Notch2lox/+ 
Cx3cr1GFP/+ 
B6 
GFP+ N1N2∆CD11c CD11cCre Notch1lox/lox Notch2lox/lox 
Cx3cr1GFP/+ 
B6 
Ctrl CD11c+/+ Notch2lox/lox B6 
N2∆CD11c CD11cCre Notch2lox/lox B6 
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Supplementary Table 3: Antibodies and fluorescence dyes for flow cytometry 
and immunofluorescence used in the study 
 
Antibody/dye Clone Dilution Company 
Anti-CD3ε 145-2C11 1:100 BioLegend 
Anti-CD49b DX5 1:400 BioLegend 
Anti-CD45R/B220 RA3-6B2 1:400 BioLegend 
Anti-Ly6G 1A8 1:400 BioLegend 
Anti-CD19 1D3 1:400 BD Pharmingen 
Anti-NK1.1 PK136 1:400 BioLegend 
Anti-CD117 2B8 1:100 BioLegend 
Anti-CD115 AFS98 1:100 BioLegend 
Anti-CD11b M1/70 1:400 BioLegend 
Anti-Ly6C HK1.4 1:2800 BioLegend 
Anti-F4/80 BM8 1:100 BioLegend 
Anti-CD11c N418 1:400 BioLegend 
Anti-I-A/I-E M5/114.15.2 1:400 BioLegend 
Anti-CD43 S7 1:400 BD Pharmingen 
Anti-CD45 30-F11 1:200 BioLegend 
Anti-CD45.1 A20 1:100 BioLegend 
Anti-CD45.2 104 1:200 BioLegend 
Anti-CD144 11D4.1 1:100 BD Pharmingen 
Anti-CX3CR1 SA011F11 1:200 BioLegend 
Anti-CD11a M17/4 1:200 BioLegend 
Anti-CCR2 475301 1:100 R&D 
Anti-Notch2 HMN2-35 1:100 BioLegend 
Anti-CD16/CD32 93 1:200 BioLegend 
Anti-CD31 Mec13.3 1:400 BD Pharmingen 
Streptavidin 
PE-Dazzle594 
 1:400 BioLegend 
Annexin V  1:50 BioLegend 
7AAD  1:100 BioLegend 
Propidium Iodide  1:12000 Sigma 
Anti-GFP  1:300 Acris 
Anti-DLL1 HMD1-3 1:100 BioLegend 
Streptavidin Cy3  1:400 BioLegend 
Anti-rabbit IgG-FITC  1:200 Jackson ImmunoResearch 
DAPI  1:5000 Invitrogen 
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Supplementary Table 4: Primers for QRT-PCR 
 
Gene Primers 
Notch2 Forward: AGTGTCAGAGGCCAGCAAGAAGAA 
Reverse: TGATTGTCGTCCATCAGAGCACCA 
Notch1 Forward: TGGAGGTCTCAGTGGCTATAA 
Reverse: ATTCTGGCATGGGTTAGAAAGA 
Hey2 Forward: TGAAGCGCCCTTGTGAGGAA 
Reverse: TTGTAGCGTGCCCAGGGTAA 
Hes1 Forward: CCGGACAAACCAAAGACGGC 
Reverse: GGAATGCCGGGAGCTATCTTTCT 
Dll1 Forward: TCCGATTCCCCTTCGGCTTC 
Reverse: TGGGTTTTCTGTTGCGAGGT 
Nr4a1 Forward: AGCTTGGGTGTTGATGTTCC 
Reverse: AATGCGATTCTGCAGCTCTT 
Pparg Forward: AGGGCGATCTTGACAGGAA 
Reverse: CACCTCTTTGCTCTGCTCCT 
Pou2f2 Forward: TGCACATGGAGAAGGAAGTG 
Reverse: AGCTTGGGACAATGGTAAGG 
Slfn5 Forward: AGGTCGAACGATTCTGCTGT 
Reverse: TCTGAGGGAAACTGGAAAGG 
Ccr2 Forward: CCTTGGGAATGAGTAACTGTGTGAT 
Reverse: ATGGAGAGATACCTTCGGAACTTCT 
Cx3cr1 Forward: GCAGAAGTTCCCTTCCCATC 
Reverse: GGACAGGAAGATGGTTCCAA 
 
